Trial Profile
A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Amphotericin B (Primary)
- Indications Mucocutaneous candidiasis
- Focus Therapeutic Use
- Acronyms CAMB
- Sponsors Aquarius Biotechnologies; Matinas BioPharma
- 17 Aug 2022 Status changed from active, no longer recruiting to completed.
- 14 Feb 2022 Planned End Date changed from 1 Dec 2021 to 31 Dec 2022.
- 22 Feb 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Dec 2021.